GBA1 and Parkinson disease: The encouraging outcomes in these AAV-based preclinical studies led to a Phase I/IIa clinical trial investigating AAV9-based GBA1 gene therapy in PD patients with at least one pathogenic GBA1 mutation (NCT04127578).